Sevion Therapeutics (SVON) 0.1500 $SVON Sevion
Post# of 273242
Posted On: 09/19/2016 7:15:14 AM
Sevion Therapeutics (SVON) 0.1500 $SVON
Sevion Therapeutics Presents Cow Antibody Platform at Protein Discovery Summit
BusinessWire - Wed Oct 21, 5:00AM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company"
(OTCBB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, MD, PhD, Chief Scientific Officer, will give an invited oral presentation entitled "Engineering Cow Antibodies with Ultralong CDRs" at the GTC Protein Discovery Summit conference in Boston, MA on October 22, 2015. "Antibodies with unique features, such as long target binding regions, are becoming more important in drug discovery. Our unique humanized cow scaffold has potential to address many challenging targets like ion channels," noted Dr. Smider. "The discovery of the structural and genetic features of cow antibodies were featured in the journal Cell just two years ago, and we are excited to share our progress in engineering these exciting next-generation antibodies for therapeutics."
Sevion Therapeutics posts higher loss of USD18.9m for fiscal 2015
M2 - Thu Oct 15, 3:06AM CDT
Biopharmaceutical company Sevion Therapeutics (OTCBB:SVON) stated on Wednesday its loss of USD18.9m (USD1.31 per common share) for the fiscal year ended 30 June 2015 (fiscal 2015).
Sevion Therapeutics Reports Fiscal Year 2015 Financial Results
BusinessWire - Wed Oct 14, 4:48PM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company" (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal year ended June 30, 2015 ("Fiscal 2015" and also provided an overview of corporate accomplishments and plans.
Sevion Therapeutics, Inc. Announces Close of Private Placement Financing for Gross Proceeds of Approximately $6.55 Million
BusinessWire - Mon Aug 03, 5:30AM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company" (OTCQB:SVON) today announced that on July 27, 2015 the Company closed a private placement with certain accredited investors (the "Offering" whereby the Company sold units consisting of shares common stock or convertible preferred stock of the Company and warrants to purchase shares of common stock for aggregate gross proceeds of approximately $6,548,963.
Sevion Therapeutics Announces Establishment of a Biophysical Characterization Applications Lab
BusinessWire - Thu Jul 30, 5:30AM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company" (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, has entered into an agreement with Malvern Instruments establishing a new biopharmaceutical applications laboratory in the heart of San Diego's biotechnology cluster. The new laboratory will enable Sevion Therapeutics and customers of Malvern the experience and use Malvern's range of specialist biophysical characterization systems in a working biopharmaceutical environment.
Sevion Therapeutics Announces Immuno Oncology Discovery Program at BIO
BusinessWire - Tue Jun 16, 12:14PM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company" (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today provided an overview of the Company's technology and programs by Dr. Miguel de los Rios, PhD, VP of Research and Development, at the BIO International Convention in Philadelphia, PA.
Sevion Therapeutics to Present at International Antibody Meeting
BusinessWire - Fri Jun 05, 7:00AM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company" (OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, M.D., Ph.D., Chief Scientific Officer, will give a presentation entitled "Cow antibodies with long CDR3s: Biology and Applications" on Monday, June 15, at the Next-Generation Antibodies and Protein Analysis: Tools and Technologies of the VIB Conference Series in Gent, Belgium as an invited speaker. "The unusual architecture of cow antibodies presents both a unique paradigm of immunity, as well as a novel scaffold for drug discovery against challenging targets," noted Dr. Smider. The first description of the cow antibody structure and genetic diversity mechanisms were featured on the cover of Cell in 2013, and Sevion has since been further advancing cow-antibody based technologies and experimental therapeutics against difficult targets, including SVN-001 which targets the Kv1.3 ion channel on activated T-cells in autoimmune conditions.
Sevion Therapeutics to Present at 2015 BIO International Convention
BusinessWire - Wed Jun 03, 7:30AM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company" (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Miguel de los Rios, Ph.D., Vice President of Research and Development, will present an overview of the Company's technology and programs at the 2015 BIO International Convention in Philadelphia, PA on June 16, 2015. "We are excited to share our discoveries and progress with the biotechnology community at BIO 2015, particularly our progress in identifying and developing antibodies against high-value difficult targets like ion channels and GPCRs," noted Dr. de los Rios. The Company employs unique strategies to discover antibodies against multipass membrane proteins, including utilization of a novel cow antibody scaffold which was featured on the cover of Cell in 2013.
Sevion Therapeutics Reports Third Quarter 2015 Financial Results
BusinessWire - Fri May 15, 7:30AM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company" (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal quarter ended March 31, 2015 ("Third Quarter 2015" .
Sevion Therapeutics Presents Cow Antibody Platform at PEGS 2015
BusinessWire - Mon May 04, 2:30PM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company" (OTCBB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, MD, PhD, Chief Scientific Officer, gave an oral presentation on the company's cow-derived ultralong CDR3 antibody platform and an update on SVN-001, its antibody targeting the ion channel Kv1.3 for autoimmune diseases, at the international PEGS conference in Boston, MA on May 4, 2015. "The unique ultralong CDR3s of cow antibodies provide a new domain for which to target traditionally difficult and high value antigens, and we are eager to share our discoveries and progress with the protein therapeutics community at PEGS 2015," noted Dr. Smider. The unique structure and genetic diversity mechanisms of cows were featured on the cover of Cell in 2013, and the company has since developed discovery and commercialization strategies based on the novel cow antibody scaffold.
Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 261.25 (+1.70), CLDX: 3.65 (-0.05), EPZM: 9.28 (+0.39), STML: 9.86 (+0.29), JNJ: 118.25 (-0.38), ABBV: 63.27 (-0.08), INFI: 1.46 (+0.06), PTLA: 23.60 (+0.57), INCY: 82.15 (+1.79), PFE: 33.94 (-0.20), IMGN: 2.83 (+0.05), AMGN: 172.96 (+0.32), LLY: 78.80 (-0.02), BMY: 55.60 (-0.37), GSK: 42.88 (-0.66), SGEN: 53.65 (+0.06), GILD: 78.80 (-0.04), KITE: 57.63 (+2.26), MRK: 62.28 (-0.10), TEVA: 51.74 (-0.16), CELGZ: 1.21 (-0.03), KPTI: 9.30 (+0.19), NVS: 79.34 (-0.54)
Sevion Therapeutics incurs higher Q2 2015 loss of USD10.8m
M2 - Thu Feb 19, 4:54AM CST
Biopharmaceutical company Sevion Therapeutics (OTC BB:SVON) disclosed on Wednesday that it recorded a loss of USD10.8m (USD0.78 per common share) for the fiscal second quarter 2015, which ended 31 December 2014.
Sevion Therapeutics Reports Second Quarter 2015 Financial Results
BusinessWire - Wed Feb 18, 4:30PM CST
Sevion Therapeutics, Inc. ("Sevion" or the "Company" (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal quarter ended December 31, 2014 ("Second Quarter 2015" .
The Market for Personalized Gene Therapy Treatments for Cancer
M2 - Fri Jan 16, 8:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ddkrc/the_market_for) has announced the addition of the "The Market for Personalized Gene Therapy Treatments for Cancer" report to their offering. This report, The Market for Personalized Gene Therapy Treatments For Cancer provides an exhaustive review of the market potential for relatively new approach in cancer research. It involves modification of genes instead of using a surgical method or chemical drug product. Essentially, gene therapies replace an abnormal gene with a normal gene, or changes the response of a gene (turn on or off). Not all of the approaches to gene therapy are the same, and different cancers appear to respond better to different therapies. Several gene therapy technologies have the ability to work in combination with other treatment options to enhance the effectiveness of a therapeutic regimen. Gene therapy is also designed to target specific cells making treatment much less damaging to healthy cells. This report discusses those treatments and estimates market size and market potential for personalized medicine using gene therapy. In addition the report provides: - Overview of Gene Therapy - Overall Market Size and Forecast - Cancer Therapeutic Market Totals - Discussion of Somati vs. Germ Line Gene Therapy - R&D Activities - Company Profiles Key Topics Covered: - Executive Summary - Gene Therapy Overview - Cancer and Gene Therapy - Gene Therapy Outlook in Bladder Cancer - Gene Therapy Outlook in Brain Cancer - Gene Therapy Outlook in Breast Cancer - Gene Therapy Outlook in Colorectal Cancer - Gene Therapy Outlook in Head & Neck Cancer - Gene Therapy Outlook in Leukemia - Gene Therapy Outlook in Liver Cancer - Gene Therapy Outlook in Lung Cancer - Gene Therapy Outlook in Lymphoma - Gene Therapy Outlook in Melanoma - Gene Therapy Outlook in Ovarian Cancer - Gene Therapy Outlook in Pancreatic Cancer - Gene Therapy Outlook in Prostate Cancer - Gene Therapy and Other Cancers - Gene Therapy in Cancer Market Summary and Outlook - Industry Participants and Contributors Companies Mentioned - Advantagene, Inc. - Amgen, Inc. - Bellicum Pharmaceuticals, Inc. - BioCancell Ltd. - Blubird Bio - Celgene - Celsion Corporation - Chengdu Shi Endor Biological Engineering Technology Co., Ltd. - Cold Genesys, Inc. - Genprex, Inc. - MaxiVax SA - Momotaro-Gene, Inc. - MultiVir, Inc. - OncoSec Medical, Inc. - Sevion Therapeutics, Inc. - SynerGene Therapeutics, Inc. - Takara Bio, Inc. - Tocagen, Inc. - VBL Therapeutics Ltd. - Ziopharm Oncology, Inc. - daptimmune Ltd. For more information visit http://www.researchandmarkets.com/research/9d...market_for
CLSN: 1.22 (unch), BLCM: 19.87 (+0.12), ONCS: 1.71 (-0.04), AMGN: 172.96 (+0.32), CELGZ: 1.21 (-0.03)
Sevion Announces Antibody Discovery Collaboration with Johnson & Johnson Innovation and Janssen
BusinessWire - Mon Dec 22, 5:30AM CST
Sevion Therapeutics Inc. ("Sevion" or the "Company" (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics, today announced a collaboration agreement with CNA Development, LLC, an affiliate of Janssen Pharmaceuticals, Inc. (Janssen) to discover antibodies using Sevion's spatially addressed library platform. The collaboration facilitated by the Johnson & Johnson Innovation center in California will include discovery of antibodies against multiple targets in several therapeutic areas. Sevion and Janssen will jointly conduct research on antibodies discovered by Sevion, and Janssen will have an option to an exclusive license to develop, manufacture, and commercialize candidates resulting from the collaboration.
JNJ: 118.25 (-0.38)
Sevion Therapeutics Presents Results of SNS01-T Phase 1b/2a Dose Escalation Study at ASH Annual Meeting
BusinessWire - Mon Dec 08, 8:00PM CST
Sevion Therapeutics (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced the presentation of results from the Company's Phase 1b/2a clinical trial of SNS01-T for the treatment of multiple myeloma and lymphoma. The results were presented in a poster session titled "Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III" at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco.
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 3.23 (+0.19), AMGN: 172.96 (+0.32), RGLS: 3.23 (-0.11), LLY: 78.80 (-0.02), GSK: 42.88 (-0.66), PVCT: 0.11 (+0.01), CANF: 2.31 (+0.03), DCTH: 4.31 (+0.33), NVS: 79.34 (-0.54), XLRN: 34.51 (+1.00)
Sevion Therapeutics Announces Chimerasome Research Agreement
BusinessWire - Mon Nov 24, 7:15AM CST
Sevion Therapeutics (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that it has entered into a research agreement with Avidity NanoMedicines LLC related to the use of Sevion's chimerasome technology for delivery of nucleic acids. Terms of the agreement were not disclosed.
Sevion Therapeutics Presents Cow Antibody Platform at Protein Discovery Summit
BusinessWire - Wed Oct 21, 5:00AM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company"
(OTCBB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, MD, PhD, Chief Scientific Officer, will give an invited oral presentation entitled "Engineering Cow Antibodies with Ultralong CDRs" at the GTC Protein Discovery Summit conference in Boston, MA on October 22, 2015. "Antibodies with unique features, such as long target binding regions, are becoming more important in drug discovery. Our unique humanized cow scaffold has potential to address many challenging targets like ion channels," noted Dr. Smider. "The discovery of the structural and genetic features of cow antibodies were featured in the journal Cell just two years ago, and we are excited to share our progress in engineering these exciting next-generation antibodies for therapeutics." Sevion Therapeutics posts higher loss of USD18.9m for fiscal 2015
M2 - Thu Oct 15, 3:06AM CDT
Biopharmaceutical company Sevion Therapeutics (OTCBB:SVON) stated on Wednesday its loss of USD18.9m (USD1.31 per common share) for the fiscal year ended 30 June 2015 (fiscal 2015).
Sevion Therapeutics Reports Fiscal Year 2015 Financial Results
BusinessWire - Wed Oct 14, 4:48PM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company"
(OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal year ended June 30, 2015 ("Fiscal 2015" and also provided an overview of corporate accomplishments and plans. Sevion Therapeutics, Inc. Announces Close of Private Placement Financing for Gross Proceeds of Approximately $6.55 Million
BusinessWire - Mon Aug 03, 5:30AM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company"
(OTCQB:SVON) today announced that on July 27, 2015 the Company closed a private placement with certain accredited investors (the "Offering" whereby the Company sold units consisting of shares common stock or convertible preferred stock of the Company and warrants to purchase shares of common stock for aggregate gross proceeds of approximately $6,548,963. Sevion Therapeutics Announces Establishment of a Biophysical Characterization Applications Lab
BusinessWire - Thu Jul 30, 5:30AM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company"
(OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, has entered into an agreement with Malvern Instruments establishing a new biopharmaceutical applications laboratory in the heart of San Diego's biotechnology cluster. The new laboratory will enable Sevion Therapeutics and customers of Malvern the experience and use Malvern's range of specialist biophysical characterization systems in a working biopharmaceutical environment. Sevion Therapeutics Announces Immuno Oncology Discovery Program at BIO
BusinessWire - Tue Jun 16, 12:14PM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company"
(OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today provided an overview of the Company's technology and programs by Dr. Miguel de los Rios, PhD, VP of Research and Development, at the BIO International Convention in Philadelphia, PA. Sevion Therapeutics to Present at International Antibody Meeting
BusinessWire - Fri Jun 05, 7:00AM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company"
(OTCQB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, M.D., Ph.D., Chief Scientific Officer, will give a presentation entitled "Cow antibodies with long CDR3s: Biology and Applications" on Monday, June 15, at the Next-Generation Antibodies and Protein Analysis: Tools and Technologies of the VIB Conference Series in Gent, Belgium as an invited speaker. "The unusual architecture of cow antibodies presents both a unique paradigm of immunity, as well as a novel scaffold for drug discovery against challenging targets," noted Dr. Smider. The first description of the cow antibody structure and genetic diversity mechanisms were featured on the cover of Cell in 2013, and Sevion has since been further advancing cow-antibody based technologies and experimental therapeutics against difficult targets, including SVN-001 which targets the Kv1.3 ion channel on activated T-cells in autoimmune conditions. Sevion Therapeutics to Present at 2015 BIO International Convention
BusinessWire - Wed Jun 03, 7:30AM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company"
(OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Miguel de los Rios, Ph.D., Vice President of Research and Development, will present an overview of the Company's technology and programs at the 2015 BIO International Convention in Philadelphia, PA on June 16, 2015. "We are excited to share our discoveries and progress with the biotechnology community at BIO 2015, particularly our progress in identifying and developing antibodies against high-value difficult targets like ion channels and GPCRs," noted Dr. de los Rios. The Company employs unique strategies to discover antibodies against multipass membrane proteins, including utilization of a novel cow antibody scaffold which was featured on the cover of Cell in 2013. Sevion Therapeutics Reports Third Quarter 2015 Financial Results
BusinessWire - Fri May 15, 7:30AM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company"
(OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal quarter ended March 31, 2015 ("Third Quarter 2015" . Sevion Therapeutics Presents Cow Antibody Platform at PEGS 2015
BusinessWire - Mon May 04, 2:30PM CDT
Sevion Therapeutics, Inc. ("Sevion" or the "Company"
(OTCBB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, MD, PhD, Chief Scientific Officer, gave an oral presentation on the company's cow-derived ultralong CDR3 antibody platform and an update on SVN-001, its antibody targeting the ion channel Kv1.3 for autoimmune diseases, at the international PEGS conference in Boston, MA on May 4, 2015. "The unique ultralong CDR3s of cow antibodies provide a new domain for which to target traditionally difficult and high value antigens, and we are eager to share our discoveries and progress with the protein therapeutics community at PEGS 2015," noted Dr. Smider. The unique structure and genetic diversity mechanisms of cows were featured on the cover of Cell in 2013, and the company has since developed discovery and commercialization strategies based on the novel cow antibody scaffold. Mantle Cell Lymphoma Therapeutics Pipeline Review 2015 - Featuring 39 Companies
M2 - Fri Mar 13, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n2r2lq/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Amgen Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - ImmunoGen, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharmacyclics, Inc. - Portola Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Sevion Therapeutics, Inc. - Stemline Therapeutics, Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/n2...antle_cell
PCYC: 261.25 (+1.70), CLDX: 3.65 (-0.05), EPZM: 9.28 (+0.39), STML: 9.86 (+0.29), JNJ: 118.25 (-0.38), ABBV: 63.27 (-0.08), INFI: 1.46 (+0.06), PTLA: 23.60 (+0.57), INCY: 82.15 (+1.79), PFE: 33.94 (-0.20), IMGN: 2.83 (+0.05), AMGN: 172.96 (+0.32), LLY: 78.80 (-0.02), BMY: 55.60 (-0.37), GSK: 42.88 (-0.66), SGEN: 53.65 (+0.06), GILD: 78.80 (-0.04), KITE: 57.63 (+2.26), MRK: 62.28 (-0.10), TEVA: 51.74 (-0.16), CELGZ: 1.21 (-0.03), KPTI: 9.30 (+0.19), NVS: 79.34 (-0.54)
Sevion Therapeutics incurs higher Q2 2015 loss of USD10.8m
M2 - Thu Feb 19, 4:54AM CST
Biopharmaceutical company Sevion Therapeutics (OTC BB:SVON) disclosed on Wednesday that it recorded a loss of USD10.8m (USD0.78 per common share) for the fiscal second quarter 2015, which ended 31 December 2014.
Sevion Therapeutics Reports Second Quarter 2015 Financial Results
BusinessWire - Wed Feb 18, 4:30PM CST
Sevion Therapeutics, Inc. ("Sevion" or the "Company"
(OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today reported financial results for the fiscal quarter ended December 31, 2014 ("Second Quarter 2015" . The Market for Personalized Gene Therapy Treatments for Cancer
M2 - Fri Jan 16, 8:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ddkrc/the_market_for) has announced the addition of the "The Market for Personalized Gene Therapy Treatments for Cancer" report to their offering. This report, The Market for Personalized Gene Therapy Treatments For Cancer provides an exhaustive review of the market potential for relatively new approach in cancer research. It involves modification of genes instead of using a surgical method or chemical drug product. Essentially, gene therapies replace an abnormal gene with a normal gene, or changes the response of a gene (turn on or off). Not all of the approaches to gene therapy are the same, and different cancers appear to respond better to different therapies. Several gene therapy technologies have the ability to work in combination with other treatment options to enhance the effectiveness of a therapeutic regimen. Gene therapy is also designed to target specific cells making treatment much less damaging to healthy cells. This report discusses those treatments and estimates market size and market potential for personalized medicine using gene therapy. In addition the report provides: - Overview of Gene Therapy - Overall Market Size and Forecast - Cancer Therapeutic Market Totals - Discussion of Somati vs. Germ Line Gene Therapy - R&D Activities - Company Profiles Key Topics Covered: - Executive Summary - Gene Therapy Overview - Cancer and Gene Therapy - Gene Therapy Outlook in Bladder Cancer - Gene Therapy Outlook in Brain Cancer - Gene Therapy Outlook in Breast Cancer - Gene Therapy Outlook in Colorectal Cancer - Gene Therapy Outlook in Head & Neck Cancer - Gene Therapy Outlook in Leukemia - Gene Therapy Outlook in Liver Cancer - Gene Therapy Outlook in Lung Cancer - Gene Therapy Outlook in Lymphoma - Gene Therapy Outlook in Melanoma - Gene Therapy Outlook in Ovarian Cancer - Gene Therapy Outlook in Pancreatic Cancer - Gene Therapy Outlook in Prostate Cancer - Gene Therapy and Other Cancers - Gene Therapy in Cancer Market Summary and Outlook - Industry Participants and Contributors Companies Mentioned - Advantagene, Inc. - Amgen, Inc. - Bellicum Pharmaceuticals, Inc. - BioCancell Ltd. - Blubird Bio - Celgene - Celsion Corporation - Chengdu Shi Endor Biological Engineering Technology Co., Ltd. - Cold Genesys, Inc. - Genprex, Inc. - MaxiVax SA - Momotaro-Gene, Inc. - MultiVir, Inc. - OncoSec Medical, Inc. - Sevion Therapeutics, Inc. - SynerGene Therapeutics, Inc. - Takara Bio, Inc. - Tocagen, Inc. - VBL Therapeutics Ltd. - Ziopharm Oncology, Inc. - daptimmune Ltd. For more information visit http://www.researchandmarkets.com/research/9d...market_for
CLSN: 1.22 (unch), BLCM: 19.87 (+0.12), ONCS: 1.71 (-0.04), AMGN: 172.96 (+0.32), CELGZ: 1.21 (-0.03)
Sevion Announces Antibody Discovery Collaboration with Johnson & Johnson Innovation and Janssen
BusinessWire - Mon Dec 22, 5:30AM CST
Sevion Therapeutics Inc. ("Sevion" or the "Company"
(OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics, today announced a collaboration agreement with CNA Development, LLC, an affiliate of Janssen Pharmaceuticals, Inc. (Janssen) to discover antibodies using Sevion's spatially addressed library platform. The collaboration facilitated by the Johnson & Johnson Innovation center in California will include discovery of antibodies against multiple targets in several therapeutic areas. Sevion and Janssen will jointly conduct research on antibodies discovered by Sevion, and Janssen will have an option to an exclusive license to develop, manufacture, and commercialize candidates resulting from the collaboration. JNJ: 118.25 (-0.38)
Sevion Therapeutics Presents Results of SNS01-T Phase 1b/2a Dose Escalation Study at ASH Annual Meeting
BusinessWire - Mon Dec 08, 8:00PM CST
Sevion Therapeutics (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced the presentation of results from the Company's Phase 1b/2a clinical trial of SNS01-T for the treatment of multiple myeloma and lymphoma. The results were presented in a poster session titled "Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III" at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco.
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 3.23 (+0.19), AMGN: 172.96 (+0.32), RGLS: 3.23 (-0.11), LLY: 78.80 (-0.02), GSK: 42.88 (-0.66), PVCT: 0.11 (+0.01), CANF: 2.31 (+0.03), DCTH: 4.31 (+0.33), NVS: 79.34 (-0.54), XLRN: 34.51 (+1.00)
Sevion Therapeutics Announces Chimerasome Research Agreement
BusinessWire - Mon Nov 24, 7:15AM CST
Sevion Therapeutics (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that it has entered into a research agreement with Avidity NanoMedicines LLC related to the use of Sevion's chimerasome technology for delivery of nucleic acids. Terms of the agreement were not disclosed.
(0)
(0)Scroll down for more posts ▼